Leanna Andrews
Primary Care · Lagrange, GANPI 1730614934
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. Reporting peaked in 2021 at $1,662 and has fallen 77.6% since, to $372 in 2025. Among primary care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$620
- AstraZeneca$528
- Bayer$419
- Xeris Pharmaceuticals, Inc.$398
- Lilly USA, LLC$275
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,130100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $1,274 |
| Abbott | 46 | $620 |
| AstraZeneca | 9 | $528 |
| Bayer | 16 | $419 |
| Xeris Pharmaceuticals, Inc. | 12 | $398 |
| Lilly USA, LLC | 18 | $275 |
| Amgen(2 entities) | 13 | $260 |
| Sanofi-aventis U.S. LLC | 7 | $208 |
| Esperion Therapeutics, Inc. | 6 | $203 |
| GSK | 5 | $193 |
| Boehringer Ingelheim | 8 | $141 |
| Dexcom, Inc. | 5 | $110 |
| Merck | 5 | $72 |
| Zealand Pharma US, Inc. | 4 | $70 |
| Bigfoot Biomedical Inc | 3 | $51 |
| Cequr Corporation | 1 | $51 |
| Mannkind Corporation | 3 | $46 |
| Recordati_rare_diseases_inc. | 2 | $42 |
| Medtronic | 2 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| AbbVie | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,130 in reported general payments places this provider in the 90th percentile of 235 primary care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $246,618 |
| JardianceEmpagliflozin | 100 | $122,116 |
| FarxigaDapagliflozin Propanediol | 86 | $112,435 |
| TrulicityDulaglutide | 31 | $41,159 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $39,242 |
| MounjaroTirzepatide | 26 | $35,331 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 25 | $26,950 |
| JanuviaSitagliptin Phosphate | 27 | $26,611 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $16,658 |
| KerendiaFinerenone | 18 | $15,178 |
| Novolog FlexpenInsulin Aspart | 45 | $14,376 |
| NovologInsulin Aspart | 36 | $13,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,336 |
| VascepaIcosapent Ethyl | 13 | $6,949 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,274 | $259,875180 claims |
| Boehringer IngelheimJardiance | $141 | $122,116100 claims |
| AstraZenecaFarxiga | $528 | $112,43586 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $275 | $82,14178 claims |
| MerckJanuvia | $72 | $26,61127 claims |
| BayerKerendia | $419 | $15,17818 claims |
| GSKTrelegy Ellipta | $193 | $8,33612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $1,069101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 primary care providers in Georgia.
Other primary care in Lagrange
- Candace WorthamLagrange$6K
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.